PBYI — Puma Biotechnology Inc

Puma Biotechnology Inc (PBYI) is a biotechnology company listed on NASDAQ. It is led by Alan H. Auerbach, based in 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024, with about 172 employees. Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Latest reported PBYI revenue for 2025-09-30 was $54.5M. Net income was $8.8M. Revenue was up 3.9% from 2025-06-30 to 2025-09-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.

Use this PBYI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PBYI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PBYI SEC filings page. Lician reads the product cache first so this HTML stays unique to Puma Biotechnology Inc even when a live quote feed is slow.